Method of Determining Sensitivity of Human or Non-Human Animal Cells to an Iap Antagonist

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a method for predicting whether human or animal cells will be sensitive or resistant to treatment with IAP (Inhibitor of Apoptosis Protein) antagonists, such as Smac mimetics, by measuring the expression of specific cFLIP protein isoforms (cFLIP< L > and cFLIPs). Cells expressing the short isoform (cFLIPs) are sensitive, while those expressing the long isoform (cFLIP< L >) are resistant. This enables more personalized and effective treatment of proliferative diseases, such as cancer or autoimmune disorders, by selecting appropriate patients for IAP antagonist therapy.

Use CasesContent extracted from patent full text and abstract with AI.

• Determining which cancer patients are likely to respond to IAP antagonist therapies in oncology, leading to more personalized cancer treatment.
• Screening proliferative cells from biopsy samples to guide therapy decisions for patients with cancers, autoimmune diseases, or benign proliferative disorders.
• Selecting patients for inclusion in clinical trials of IAP antagonist therapies based on their likelihood of response.
• Designing diagnostic kits for hospitals and laboratories to test cFLIP isoform expression and predict treatment outcomes.
• Researching mechanisms of apoptosis resistance in various cell types to develop more effective apoptosis-based therapies.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a biomarker-driven approach, enabling personalized medicine by predicting tumor or disease cell responsiveness to IAP antagonists.
• Prevents unnecessary treatment (and potential side effects) in patients unlikely to respond to IAP antagonists, improving healthcare efficiency.
• Facilitates selection of patients for clinical trials, enhancing chances of successful study outcomes.
• Allows adjustment or combination of treatments if resistance is predicted, optimizing therapeutic strategies.
• Enables development of diagnostic kits that support oncologists and clinicians in making evidence-based treatment decisions.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

cFLIP serves as a biomarker for efficacy of treatment with IAP antagonists, including Smac peptidomimetics.